Randy Teel Sells 4,786 Shares of Arvinas (NASDAQ:ARVN) Stock

Arvinas, Inc. (NASDAQ:ARVN) CEO Randy Teel sold 4,786 shares of the business’s stock in a transaction dated Monday, February 23rd. The stock was sold at an average price of $12.16, for a total transaction of $58,197.76. Following the completion of the sale, the chief executive officer owned 149,696 shares in the company, valued at approximately $1,820,303.36. This trade represents a 3.10% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website.

Randy Teel also recently made the following trade(s):

• On Friday, February 13th, Randy Teel sold 4,403 shares of Arvinas stock. The shares were sold at an average price of $11.89, for a total transaction of $52,351.67.

Arvinas Price Performance

NASDAQ ARVN opened at $13.38 on Friday. Arvinas, Inc. has a 12 month low of $5.90 and a 12 month high of $18.93. The company has a market capitalization of $855.78 million, a P/E ratio of -10.45 and a beta of 1.88. The company’s 50 day simple moving average is $12.45 and its 200 day simple moving average is $10.55.

Arvinas (NASDAQ:ARVN) last posted its quarterly earnings results on Tuesday, February 24th. The company reported ($1.10) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.55) by ($0.55). The business had revenue of $9.50 million during the quarter, compared to analyst estimates of $37.26 million. Arvinas had a negative return on equity of 14.25% and a negative net margin of 30.77%.The company’s quarterly revenue was down 84.0% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.63) EPS. On average, analysts anticipate that Arvinas, Inc. will post -3.81 earnings per share for the current year.

Institutional Investors Weigh In On Arvinas

Several large investors have recently made changes to their positions in ARVN. AQR Capital Management LLC bought a new stake in Arvinas in the first quarter worth approximately $727,000. Jacobs Levy Equity Management Inc. bought a new position in shares of Arvinas during the 1st quarter valued at $301,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in shares of Arvinas by 5.8% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 38,636 shares of the company’s stock valued at $271,000 after purchasing an additional 2,122 shares during the last quarter. Millennium Management LLC boosted its holdings in Arvinas by 208.4% in the first quarter. Millennium Management LLC now owns 1,310,326 shares of the company’s stock worth $9,198,000 after purchasing an additional 885,483 shares in the last quarter. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its position in Arvinas by 108.3% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 902,925 shares of the company’s stock worth $6,339,000 after buying an additional 469,394 shares during the last quarter. Institutional investors own 95.19% of the company’s stock.

Key Stories Impacting Arvinas

Here are the key news stories impacting Arvinas this week:

• Positive Sentiment: Piper Sandler reiterated an “overweight” rating and raised its price target to $20, signaling meaningful upside versus the current price. Read More.
• Positive Sentiment: Media coverage highlighted Arvinas’ PROTAC pipeline and upcoming clinical catalysts, which helped lift futures sentiment and investor interest. Read More.
• Positive Sentiment: Company commentary confirmed 2026 clinical-data milestones and a cash runway into the second half of 2028, lowering near-term financing risk for ongoing programs. Read More.
• Neutral Sentiment: Benzinga summarized several recent analyst actions and commentary on ARVN; it aggregates views rather than providing new catalysts. Read More.
• Neutral Sentiment: Street consensus remains mixed — MarketBeat/AmericanBankingNews show a consensus “Hold” despite multiple buy/overweight calls, so analyst sentiment is not uniform. Read More.
• Neutral Sentiment: Reported short-interest figures for February contain anomalies (0 shares / NaN), so short-interest/read-throughs are unreliable until corrected data is published. (Data report entry)
• Negative Sentiment: Q4 results were a clear negative: ARVN missed EPS and revenue estimates, with revenue down ~84% y/y — that earnings miss is the primary fundamental pressure on the stock. Read More.
• Negative Sentiment: Insider selling: CEO Randy Teel sold 4,786 shares and CAO David K. Loomis sold 1,108 shares on Feb. 23 — modest reductions that can be perceived negatively by some investors. Read More. • Read More.

Wall Street Analyst Weigh In

ARVN has been the subject of a number of recent analyst reports. Wells Fargo & Company decreased their price target on Arvinas from $16.00 to $15.00 and set an “overweight” rating for the company in a research report on Thursday, November 6th. Wedbush raised their target price on shares of Arvinas from $9.00 to $11.00 and gave the stock a “neutral” rating in a report on Tuesday. Stephens lifted their target price on shares of Arvinas from $14.00 to $15.00 and gave the stock an “overweight” rating in a research report on Monday, November 10th. Citigroup raised Arvinas from a “neutral” rating to a “buy” rating and upped their price target for the company from $10.00 to $15.00 in a research report on Tuesday, January 6th. Finally, Piper Sandler reiterated an “overweight” rating and issued a $20.00 price objective (up from $16.00) on shares of Arvinas in a research note on Wednesday. Ten investment analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and an average price target of $13.47.

About Arvinas

Arvinas, Inc (NASDAQ: ARVN) is a biopharmaceutical company focused on the development of therapies based on targeted protein degradation. Utilizing its proprietary proteolysis-targeting chimera (PROTAC®) platform, Arvinas aims to selectively eliminate disease-causing proteins rather than merely inhibit their activity. This novel approach has the potential to address a range of diseases, including oncology, neurodegeneration and inflammation, by harnessing the body’s natural protein-recycling systems.

The company’s most advanced clinical candidates address hormone-driven cancers.